Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' EQUITY

v3.19.2
STOCKHOLDERS' EQUITY
6 Months Ended
Jun. 30, 2019
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
 
Dividends

The following table summarizes the Company’s cash dividend activity for the six months ended June 30, 2019 (in thousands, except per share data):
Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
January 27, 2019 (special)
 
0.08

 
$
912

 
March 5, 2019
 
March 15, 2019
January 27, 2019
 
0.16

 
$
1,824

 
March 5, 2019
 
March 15, 2019
 
 
$
0.24

 
$
2,736

 
 
 
 


Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

Stock Repurchases

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and
regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued.

On May 16, 2019, the Company’s Board of Directors authorized the Company to proceed with the purchase of up to $8.0 million in shares of common stock under the foregoing stock repurchase program. In connection therewith, the Company was advised that George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest. See Note 10.

During May 2019, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $4.7 million in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. The open market repurchases were completed on May 31, 2019. The stock repurchases, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of 612,729 shares of its common stock for an aggregate purchase price of $6.7 million, plus transaction costs.

As of June 30, 2019, $25.3 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

Restricted Stock

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At June 30, 2019, 2,337,068 shares remained available for issuance under the 2016 Plan.

On February 1, 2019, the Company granted 22,603 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2018 performance incentives totaling $377,000. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2018
45,486

 
$
21.61

Granted
22,603

 
16.67

Vested
(22,917
)
 
23.28

Nonvested at June 30, 2019
45,172

 
18.28



Accumulated Other Comprehensive Loss
 
The changes in accumulated other comprehensive loss by component for the first six months of 2019 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Gains/(Losses) on Available-For-Sale Investments
 
Total
Balance, December 31, 2018
$
(1,217
)
 
$
(33
)
 
$
(1,250
)
Other comprehensive income
47

 
11

 
58

Balance, June 30, 2019
$
(1,170
)
 
$
(22
)
 
$
(1,192
)